For the second time this year, ImaRx Therapeutics Inc. has received a warning form Nasdaq that its stock will be delisted.
Nasdaq says ImaRx stockholder equity, market value of securities and the fact that it is continuing to show operating losses all put it below minimum standards for listing.
|
|
The issue may be a moot point since ImaRx stock price has failed to close above $1 per share for at least 10 days, which it must do by Oct. 8 to avoid being delisted under a notice issued by Nasdaq in April.
Comments